Why it may be a 'grave mistake' for FDA to wait much longer for full COVID-19 vaccine approval
Zeynep Tufecki, a sociologist who has written extensively on COVID-19 throughout the pandemic, is a proponent of broadening vaccine mandates in the United States, citing precedent in the health-care sector, the military, and schools.
Kentucky, she notes in a piece published Saturday in The New York Times, requires anyone working in a long-term care facility to be vaccinated against the flu and pneumococcal disease unless they have a medical or religious exemption (Brown University's Dr. Ashish Jha, another prominent voice during the pandemic, also pointed to flu vaccine mandates in nursing homes as a reason to implement them for the coronavirus). But Tufecki acknowledged that the fact that the Food and Drug Administration has still not granted full authorization for the Pfizer-BioNTech, Moderna, and Johnson & Johnson vaccines is an obstacle to imposing such requirements.
Both Pfizer and Moderna, which were granted emergency use late last year, have submitted their applications for full approval, and the former is apparently set to receive the green light no later than January 2022. Tufecki, for one, hopes the stamp comes much more quickly than that, however. "It would be a grave mistake for the agency to take another six months," she writes for the Times, explaining that the extra waiting time "has allowed some anti-vaxxers to claim the vaccines are experimental."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Additionally, she argues the holdup "helps feed a misunderstanding" about adverse side effects. The consensus among medical experts is that allergic reactions would occur shortly after inoculation, while other immune reactions could theoretically take longer, but would likely still occur "within the first few weeks and months after vaccination." Waiting, therefore, may suggest to some that the risk of those issues occurring down the line is higher than it is. At this point, Tufecki believes regulators have the six months of data they need, and should move quickly toward approval with the goal of increasing the U.S. vaccination rate again. Read Tufecki's full piece at The New York Times.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Cautious optimism surrounds plans for the world's first nuclear fusion power plant
Talking Point Some in the industry feel that the plant will face many challenges
By Justin Klawans, The Week US Published
-
Explore new worlds this winter at these 6 enlightening museum exhibitions
The Week Recommends Discover the estrados of Spain and the connection between art and chess in various African countries
By Catherine Garcia, The Week US Published
-
2024: the year of Black country artists
In the Spotlight Beyoncé debuted 'Cowboy Carter' at the top of the country charts, shining a spotlight on artists like Shaboozey
By Theara Coleman, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published
-
California declares bird flu emergency
Speed Read The emergency came hours after the nation's first person with severe bird flu infection was hospitalized
By Rafi Schwartz, The Week US Published
-
Bird flu one mutuation from human threat, study finds
Speed Read A Scripps Research Institute study found one genetic tweak of the virus could enable its spread among people
By Peter Weber, The Week US Published
-
Dark chocolate tied to lower diabetes risk
Speed Read The findings were based on the diets of about 192,000 US adults over 34 years
By Peter Weber, The Week US Published
-
ACA opens 2025 enrollment, enters 2024 race
Speed Read Mike Johnson promises big changes to the Affordable Care Act if Trump wins the election
By Peter Weber, The Week US Published
-
McDonald's sued over E. coli linked to burger
Speed Read The outbreak has sickened at least 49 people in 10 states and left one dead
By Rafi Schwartz, The Week US Published
-
Long Covid: study shows damage to brain's 'control centre'
The Explainer Research could help scientists understand long-term effects of Covid-19 as well as conditions such as MS and dementia
By The Week UK Published
-
FDA OKs new Covid vaccine, available soon
Speed read The CDC recommends the new booster to combat the widely-circulating KP.2 strain
By Peter Weber, The Week US Published